Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
Western University · Icahn School of Medicine at Mount Sinai · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
221
total citations
- FWCI
- 64.45
- Percentile
- 100%
- References
- 28
Citations per year
Authors
63Topics & keywords
Topics
Keywords
- Golimumab
- Medicine
- Ulcerative colitis
- Internal medicine
- Randomization
- Randomized controlled trial
- Clinical endpoint
- Clinical trial
No related works found for this paper.